靶点- |
作用机制- |
|
|
|
|
最高研发阶段临床1期 |
首次获批国家/地区- |
首次获批日期- |
Part A: Phase IB, Single Site, Dose-Escalation of SCD-101 and Part B: Randomized, Double-Blind, Placebo-Controlled Crossover of SCD-101 in Adults With Homozygous Sickle Cell Disease or S/Beta 0 Thalassemia.
The purpose of this study is to determine the safety and clinical effects of SCD-101 when given to adults with sickle cell disease.
100 项与 Invenux, Inc. 相关的临床结果
0 项与 Invenux, Inc. 相关的专利(医药)
100 项与 Invenux, Inc. 相关的药物交易
100 项与 Invenux, Inc. 相关的转化医学